Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating safety, tolerability, PK and PD in cystic fibrosis patients with at least one G542X allele has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Snippet

Sponsor: Eloxx Pharmaceuticals, Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED